[go: up one dir, main page]

BR112021005702A8 - Método para selecionar neoepítopos - Google Patents

Método para selecionar neoepítopos

Info

Publication number
BR112021005702A8
BR112021005702A8 BR112021005702A BR112021005702A BR112021005702A8 BR 112021005702 A8 BR112021005702 A8 BR 112021005702A8 BR 112021005702 A BR112021005702 A BR 112021005702A BR 112021005702 A BR112021005702 A BR 112021005702A BR 112021005702 A8 BR112021005702 A8 BR 112021005702A8
Authority
BR
Brazil
Prior art keywords
selecting
neoepitopes
mhc
selecting neoepitopes
classifying
Prior art date
Application number
BR112021005702A
Other languages
English (en)
Other versions
BR112021005702A2 (pt
Inventor
Monika Sekelja
Karoline Schjetne
Agnete Brunsvik Fredriksen
Original Assignee
Vaccibody As
Nykode Therapeutics AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccibody As, Nykode Therapeutics AS filed Critical Vaccibody As
Publication of BR112021005702A2 publication Critical patent/BR112021005702A2/pt
Publication of BR112021005702A8 publication Critical patent/BR112021005702A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MÉTODO PARA SELECIONAR NEOEPÍTOPOS. para um indivíduo, selecionando neoepítopos de ligação ao MHC I e/ou MHC II e classificando-os com relação a suas utilidades clínicas. A presente invenção também fornece vacinas contra câncer obtidas pelos métodos conforme descrito neste documento.
BR112021005702A 2018-09-27 2019-09-27 Método para selecionar neoepítopos BR112021005702A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18197172 2018-09-27
EP18197172.2 2018-09-27
PCT/EP2019/076210 WO2020065023A1 (en) 2018-09-27 2019-09-27 Method for selecting neoepitopes

Publications (2)

Publication Number Publication Date
BR112021005702A2 BR112021005702A2 (pt) 2021-06-22
BR112021005702A8 true BR112021005702A8 (pt) 2022-11-08

Family

ID=63794302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021005702A BR112021005702A8 (pt) 2018-09-27 2019-09-27 Método para selecionar neoepítopos

Country Status (12)

Country Link
US (1) US12462898B2 (pt)
EP (1) EP3856957A1 (pt)
JP (1) JP7585195B2 (pt)
KR (1) KR102902460B1 (pt)
CN (1) CN112771214B (pt)
AU (1) AU2019346023B2 (pt)
BR (1) BR112021005702A8 (pt)
CA (1) CA3111903A1 (pt)
IL (1) IL281771B2 (pt)
MX (1) MX2021003654A (pt)
SG (1) SG11202101965QA (pt)
WO (1) WO2020065023A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020221783A1 (en) * 2019-04-29 2020-11-05 Vaccibody As Methods for pre-selection of neoepitopes
JP2023549342A (ja) * 2020-11-06 2023-11-24 アマゾン テクノロジーズ インコーポレイテッド 個別化されたがんワクチンのためのネオアンチゲンの選択
GB202102606D0 (en) * 2021-02-24 2021-04-07 Univ Oxford Innovation Ltd Treatment of ovarian cancer minimal residual disease
KR20230164118A (ko) 2021-03-26 2023-12-01 니코데 테라퓨틱스 에이에스에이 암 치료를 위한 치료 조합
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
KR20240019135A (ko) 2021-05-10 2024-02-14 니코데 테라퓨틱스 에이에스에이 작제물과 면역자극 화합물의 공동발현
WO2023244997A1 (en) * 2022-06-13 2023-12-21 The University Of North Carolina At Chapel Hill Compositions and methods for inducing anticancer immunity
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
KR102857635B1 (ko) * 2022-11-08 2025-09-10 인바이츠지노믹스 주식회사 면역원성이 높은 유사체를 디자인하는 방법 및 이를 이용한 장치
EP4615980A1 (en) 2022-11-09 2025-09-17 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
WO2024216073A1 (en) * 2023-04-14 2024-10-17 The Trustees Of Columbia University In The City Of New York Engineered microbes comprising tumor neoantigen vectors for cancer immunotherapy
US20250232833A1 (en) * 2024-01-13 2025-07-17 Noergaard Anders Kaare Cyclin D1 Based Cancer Vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105648056A (zh) 2010-05-14 2016-06-08 综合医院公司 鉴定肿瘤特异性新抗原的组合物和方法
RU2670745C9 (ru) 2011-05-24 2018-12-13 Бионтех Рна Фармасьютикалс Гмбх Индивидуализированные противоопухолевые вакцины
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
CA3137846A1 (en) 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2015050158A1 (ja) 2013-10-01 2015-04-09 国立大学法人三重大学 抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン
EP3936145A1 (en) 2014-07-31 2022-01-12 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
WO2016040900A1 (en) 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
US10317402B2 (en) 2014-12-03 2019-06-11 Verik Bio, Inc. Identification, selection and use of high curative potential T cell epitopes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
AU2016260540B2 (en) * 2015-05-13 2021-01-07 Agenus Inc. Vaccines for treatment and prevention of cancer
JP2018524008A (ja) 2015-07-14 2018-08-30 パーソナル ジノーム ダイアグノスティクス， インコーポレイテッド ネオアンチゲン分析
BR112018012374A2 (pt) 2015-12-16 2018-12-04 Gritstone Oncology, Inc. identificação, fabricação e uso de neoantígeno
US12331359B2 (en) * 2017-01-18 2025-06-17 Michael Laessig Neoantigens and uses thereof for treating cancer
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules

Also Published As

Publication number Publication date
CN112771214A (zh) 2021-05-07
KR20210065171A (ko) 2021-06-03
CA3111903A1 (en) 2020-04-02
IL281771B2 (en) 2025-08-01
KR102902460B1 (ko) 2025-12-19
WO2020065023A1 (en) 2020-04-02
AU2019346023A1 (en) 2021-03-25
IL281771B1 (en) 2025-04-01
CN112771214B (zh) 2025-06-13
EP3856957A1 (en) 2021-08-04
AU2019346023B2 (en) 2024-12-12
SG11202101965QA (en) 2021-04-29
JP7585195B2 (ja) 2024-11-18
US12462898B2 (en) 2025-11-04
IL281771A (en) 2021-05-31
MX2021003654A (es) 2021-05-28
US20210388438A1 (en) 2021-12-16
JP2022502416A (ja) 2022-01-11
BR112021005702A2 (pt) 2021-06-22

Similar Documents

Publication Publication Date Title
BR112021005702A8 (pt) Método para selecionar neoepítopos
EP4219559A3 (en) Antibodies for lilrb2
MX2020001879A (es) Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
MX2019011148A (es) Metodos de tratamiento.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
WO2019094692A3 (en) Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment
PH12017500890A1 (en) Antibody drug conjugates
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CY1118761T1 (el) Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3)
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX367661B (es) Anticuerpos anti-baff novedosos.
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
EA201891983A8 (ru) Комбинированная терапия антителами к cd73
JO3714B1 (ar) تركيبات الجسم المضاد لـ cd70 و cd3
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
TN2016000472A1 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer.
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
BR122020024446B8 (pt) Compostos para modulação da expressão do receptor do hormônio de crescimento
AU2015249633A8 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
MX2019000641A (es) Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
MX2023006415A (es) Anticuerpos, usos y metodos.
MX2021003180A (es) Métodos y kits para preparar sangre entera con inactivación de patógenos.
CY1122728T1 (el) Αντισωματα εναντι hpa-1a

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NYKODE THERAPEUTICS AS (NO)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NYKODE THERAPEUTICS ASA (NO)